Besides, some other inhibitory immune checkpoint molecules, such as LAG3, TIGIT, and HAVCR2, were also highly expressed in CD103+CD8+TILs in human HCC or ICC tissues, suggesting that those CD103+CD8+TILs were also the vital population in response to the immune checkpoint blockade therapy targeting LAG3, TIGIT or TIM3, or even in combination with anti-PD-1. The gene discussed is TIGIT; the disease is hepatocellular carcinoma.